Name of Project: CTO: Assessment of Potential
Interactions Between Intravenous Methamphetamine and Oral Selegiline
Principal Investigator: Thomas Newton, M.D.
Project Director: Nicolette van Sluis, M.A.
Funding Agency: National Institute on Drug Abuse
(NIDA)
Funding Period: February 2000-February 2005
Scope of Project: This is a human laboratory
clinical pharmacology study to assess potential interactions between
intravenous methamphetamine challenge and treatment with oral
selegiline. The primary aim is to assess safety prior to undertaking
an outpatient clinical trial of selegiline for the treatment of
methamphetamine abuse/dependence. This is a singleblind inpatient
study in which, after establishing eligibility, subjects will
be randomized into one of two treatment groups (placebo [n = 8]
or 5 mg twice daily oral selegiline [n = 8]). All subjects will
receive repeated intravenous methamphetamine challenges (0, 15,
30 mg) before placebo/selegiline administration (baseline challenge
sessions) and five days after daily placebo/selegiline administration
(treatment challenge sessions). Subjects randomized to the selegiline
group will undergo 18-FDG PET and have an MRI scan. After discharge,
subjects will return weekly for two weeks of safety follow-ups.
For more information, contact Thomas
Newton.
Last updated - 07/29/2003
Last reviewed - 07/28/3003